Catalog No.
DHC82403
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Chimeric
Isotype
IgG4-kappa
Clonality
Monoclonal
Target
MAPTL, Paired helical filament-tau, MTBT1, Microtubule-associated protein tau, TAU, Neurofibrillary tangle protein, MAPT, PHF-tau
Concentration
1.24 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P10636
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
ABBV-8E12, C2N-8E12, CAS: 2096513-89-0
Clone ID
Tilavonemab
Alzheimer's disease: Recent treatment strategies, PMID: 32941929
Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial, PMID: 33609476
Lessons learned from a progressive supranuclear palsy trial, PMID: 33609464
Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies, PMID: 29181488
Comparative the efficacy and safety of Gosuranemab, Semorinemab, Tilavonemab, and Zagotenemab in patients with Alzheimer's disease: a systematic review and network meta-analysis of randomized controlled trials., PMID:39945003
Limitations and potential strategies of immune checkpoint blockade in age-related neurodegenerative disorders., PMID:39313800
Proteostasis as a fundamental principle of Tau immunotherapy., PMID:39074206
Assessing tilavonemab efficacy in early Alzheimer's disease via longitudinal item response theory modeling., PMID:38835820
Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology model., PMID:37658103
Passive tau-based immunotherapy for tauopathies., PMID:37620094
The most valuable player or the tombstone: is tau the correct target to treat Alzheimer's disease?, PMID:37150887
Tilavonemab in early Alzheimer's disease: results from a phase 2, randomized, double-blind study., PMID:36730056
An autopsy case of progressive supranuclear palsy treated with monoclonal antibody against tau., PMID:36593715
Neuropathology of progressive supranuclear palsy after treatment with tilavonemab - Author's reply., PMID:34536400
Neuropathology of progressive supranuclear palsy after treatment with tilavonemab., PMID:34536399
Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial., PMID:33609476
Lessons learned from a progressive supranuclear palsy trial., PMID:33609464
Alzheimer's disease: Recent treatment strategies., PMID:32941929
Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies., PMID:29181488
For research use only. Not for human or drug use.
